



Agenda: April 15, 2025



**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**
NOTE: This special called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, April 15, 2025
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In
Join the meeting now Meeting ID: 235 021 824 269 Passcode: BE9w5qG7 Download Teams Join on the web	+1-858-252-2734 (US Toll) Phone Conference ID: 148 347 296#

AGENDA

- I. **Call to Order and Welcome**
- II. **Executive Session (upon request)**
- III. **Old Business**
 - a. Approval of January 2025 Meeting Minutes
- IV. **New Business**
 - a. New Products to Market to be Reviewed as Single Products:
 - i. Alyftrek™ (Non-PDL)
 - ii. Sofdra™ (Non-PDL)
 - iii. Ryzumvi™ (Non-PDL)
 - iv. Crenessity™ (Non-PDL)
 - v. Journavx™ (Non-PDL)
 - vi. Tryngolza™ (Non-PDL)
 - vii. Hympavzi™ (Non-PDL)
 - viii. Alhemo® (Non-PDL)
- V. **Therapeutic Classes with Recommended Changes**
 - a. Narcotics, Long-Acting
 - b. Colony Stimulating Factors
 - c. Erythropoiesis Stimulating Proteins
 - d. Phosphate Binders
 - e. Insulins & Related Agents
 - f. Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
 - g. Growth Hormones



VI. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none">• Narcotic Agonist/Antagonists• Narcotics, Fentanyl Buccal Products• Narcotics, Short-Acting• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)• Opiate Dependence Treatments• Antihyperuricemics• Sickle Cell Anemia Treatments• Thrombopoiesis Stimulating Proteins• Alpha-Glucosidase Inhibitors• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists	<ul style="list-style-type: none">• Meglitinides• Metformins• Sulfonylureas• Thiazolidinediones (TZDs)• Androgenic Agents• Bone Resorption Suppression & Related Agents• Glucagon Agents• Pancreatic Enzymes• Progestins for Cachexia• Steroids, Oral• Uterine Disorder Treatments
--	--

VII. Adjournment

- a. Schedule of Upcoming Meetings
- July 15, 2025**
 - October 14, 2025**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.